|
Hemato-oncology / Review
Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances
Robert Kridel
Korean J Intern Med. 2025;40(3):371-393. Published online February 21, 2025
Follicular lymphoma (FL) is the most common type of indolent lymphoma, and the prognosis is favorable for most patients. However, FL remains generally incurable, and relapse is common. Patients are at risk of developing treatment-resistant lymphoma, particularly when early disease progression occurs..
|
|
|
Hemato-oncology / Original Article
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2024;39(3):501-512. Published online January 30, 2024
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).
Methods: This multicenter prospective cohort study enrolled newly diagnosed pat..
|
|
|
Hemato-oncology / Original Article
Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas
Ga-Young Song, Sung-Hoon Jung, Seo-Yeon Ahn, Mihee Kim, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Jang Bae Moon, Su Woong Yoo, Seong Young Kwon, Jung-Joon Min, Hee-Seung Bom, Sae-Ryung Kang, Deok-Hwan Yang
Korean J Intern Med. 2024;39(2):327-337. Published online January 25, 2024
Background/Aims: The prognostic significance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) in peripheral T-cell lymphomas (PTCLs) are controversial. We explored the prognostic impact of sequential 18F-FDG PET/CT during frontline chemo..
|
|
|
Hemato-oncology / Original Article
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
Min Ji Jeon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim
Korean J Intern Med. 2023;38(6):893-902. Published online August 21, 2023
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.
Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasi..
|
|
|
Hemato-oncology / Original Article
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study
Dong Won Baek, Dae Young Kim, Sang Kyun Sohn, Youngil Koh, Sung-Hoon Jung, Ho-Young Yhim, Yunsuk Choi, Joon Ho Moon
Korean J Intern Med. 2021;36(6):1471-1485. Published online September 24, 2021
Background/Aims: The objective of this study was to evaluate the efficacy and feasibility of the pediatric-inspired regimen of the adult acute lymphoblastic leukemia (ALL) Working Party, the Korean Society of Hematology.
Methods: Data of 99 patients with newly diagnosed ALL, who were treated with t..
|
|
|
Hemato-oncology / Original Article
The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim
Korean J Intern Med. 2021;36(6):1459-1470. Published online October 21, 2021
Background/Aims: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment..
|
|
|
Hemato-oncology / Original Article
Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
Yu Ri Kim, Soo-Jeong Kim, Yong Park, Sung Yong Oh, Hwan-Jung Yun, Yeung-Chul Mun, Jin Seok Kim; the Korean Society of Hematology Lymphoma Working Party
Korean J Intern Med. 2021;36(5):1181-1189. Published online July 16, 2021
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocy..
|
|
|
Hemato-oncology / Original Article
Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system
Sang Eun Yoon, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2020;35(4):946-956. Published online November 25, 2019
Background/Aims: There are limited data about the influence of the central nervous system (CNS) involvement on the prognosis for patients with the Asian variant of intravascular large B-cell lymphoma (IVLBCL).
Methods: We analyzed 46 patients who were diagnosed with IVLBCL between 2001 and 2018. Al..
|
|
|
Hemato-oncology / Original Article
Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
Hee Kyung Kim, Wonseok Kang, Dong Hyun Sinn, Joon Hyeok Lee, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2020;35(1):194-204. Published online April 4, 2019
Background/Aims: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL).
Methods: A cross-sectional study analyzed FL patients who were ..
|
|
|
Hemato-oncology / Original Article
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2019;34(5):1116-1124. Published online June 29, 2018
Background/Aims: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factor..
|
|
|
Hemato-oncology / Original Article
Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
Koung Jin Suh, Ki Hwan Kim, Ryul Kim, Ja Min Byun, Miso Kim, Jin Hyun Park, Bhumsuk Keam, Tae Min Kim, Jin-Soo Kim, In Sil Choi, Dae Seog Heo
Korean J Intern Med. 2019;34(4):894-901. Published online February 23, 2018
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography-computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear.
Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118..
|
|
|
Hemato-oncology / Original Article
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Korean J Intern Med. 2019;34(4):885-893. Published online November 20, 2017
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.
Methods..
|
|
|
Hemato-oncology / Original Article
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation
So Yeon Jeon, Ho-Young Yhim, Hee Sun Kim, Jeong-A Kim, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2018;33(6):1169-1181. Published online January 8, 2018
Background/Aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL) is limited.
Methods: Consecutive patients with aggressive NHL ..
|
|
|
Letter to the editor
Synchronous diffuse large B-cell lymphoma of the small intestine and adenocarcinoma of the colon
Ji Hyun Yang, Jain Lee, Shin Bum Kim, Seon Hoo Kim, Guk Jin Lee
Korean J Intern Med. 2018;33(2):438-441. Published online November 10, 2017
|
|
|
Letter to the editor
Intracranial relapse as a solitary mass of ocular adnexal lymphoma of the mucosa-associated lymphoid tissue type
Jung-Ho Kim, Young-Woo Jeon, Byung-Ock Choi, Gyeongsin Park, Yong-Kil Hong, Suk-Woo Yang, Seok-Goo Cho
Korean J Intern Med. 2018;33(1):224-227. Published online September 7, 2016
|
|
|
Letter to the editor
Wernicke encephalopathy as initial presentation of lymphoma
Ju Hyun Seo, Ju Hee Kim, Der Sheng Sun, Hye Sung Won, Jeong Wook Park, Yoon Ho Ko
Korean J Intern Med. 2017;32(6):1112-1114. Published online January 25, 2016
|
|
|
Hemato-oncology / Original Article
Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
Seul Lee, Dong Hyun Kim, Sung Yong Oh, So Yeon Kim, Myeong Seok Koh, Ji Hyun Lee, Suee Lee, Sung-Hyun Kim, Jong-Young Kwak, Min Gyoung Pak, Mi Ha Ju, Hyo-Jin Kim, Jin Sook Jeong
Korean J Intern Med. 2017;32(2):335-344. Published online March 11, 2016
Background/Aims: CD11c is a dendritic cell marker in humans, which potentially induces a cytotoxic effect on lymphoma cells. Forkhead boxP3 (FOXP3) is a regulator of T lymphocyte in the microenvironment of the lymphoma. The principal objective of this study was to determine whether the tumors’ mic..
|
|
|
Hemato-oncology / Review
Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party
Yong Park, Byung Bae Park, Ji Yun Jeong, Wook Youn Kim, Seongsoo Jang, Bong Kyung Shin, Dong Soon Lee, Jae Ho Han, Chan-Jeoung Park, Cheolwon Suh, Insun Kim, Hyun-Sook Chi
Korean J Intern Med. 2016;31(6):1030-1041. Published online November 1, 2016
In September 2011, the Korean Society of Hematology Lymphoma Working Party held a nationwide conference to establish a consensus for assessing bone marrow (BM) involvement in patients with lymphoma. At this conference, many clinicians, hematopathologists, and diagnostic hematologists discussed vario..
|
|
|
Hemato-oncology / Original Article
Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study
Young-Woo Jeon, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Woo-Sung Min, Seok-Goo Cho
Korean J Intern Med. 2015;31(5):944-952. Published online July 7, 2016
Background/Aims: Recently, large cohort studies regarding associations between autoimmune disease and lymphomas have been reported in a few Western countries. However, Asian data concerning autoimmune-related lymphomas are limited. Therefore, we evaluated the clinical characteristics and prognostic ..
|
|
|
Letter to the editor
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
Hyungwoo Cho, Dok Hyun Yoon, Jwa Hoon Kim, Young Bo Ko, Byoung Soo Kwon, In-Hye Song, Cheolwon Suh
Korean J Intern Med. 2016;31(3):605-607. Published online March 12, 2016
|
|
|
